Breast and lung diseases
Conditions
Interventions
Gold Standard:Pathologic diagnosis based on a biopsy surgery or therapeutic surgery, or a follow-up record that is at least greater than 6 months old.
Index test:1. General clinical information that includes tumor size, BMI, etc
2. Radiomics features of multi-modal multi-temporal imaging and optical examinations, multi-modal examination types including ultrasound, color doppler, elastography, mammogram, MRI, chest CT, 3D Opti
3. Metabolomics, genomics, transcriptomics, proteomics, lipidomics, Raman spectroscopy and other histological information of blood, exhaled gas, saliva, urine and stool specimens
4. Metabolomics, genomics, transcriptomics, proteomics, lipidomics, Raman spectroscopy, etc. of the cancerous tumor and the fresh tissue next to the cancer
5. Pathohistology and Raman spectroscopy information of paraffin HE-stained sections of cancerous and paraneoplastic tissues.
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Patients with breast disease, patients with lung disease, patients with both breast and lung disease and normal population; 2.Those who have undergone multi-modal ultrasonography, mammogram, MRI, chest CT, DOT optical imaging, Raman spectroscopy and other single or multi-omics examinations before biopsy or surgical treatment, and whose original image data are complete, and the image pictures are clear in line with the quality requirements of deep learning analysis; 3.Clear pathologic results obtained by puncture biopsy, surgical biopsy, or a follow-up record of at least greater than 6 months; 4.Patients with complete clinical information and general demographic information.
Exclusion criteria
Exclusion criteria: 1.Patients who underwent biopsy procedures such as VAB, mastoidoscopy, lumpectomy, and intra-operative freezing prior to the relevant imaging examination, i.e., patients whose lesions were already removed from the body when the examination was done; 2.Those with poor image quality of relevant imaging examinations, with artifacts or partial loss of images; 3.Those with incomplete patient information and case data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| age;Menstrual status;Personal Cancer History;Family history of cancer;mastalgia;BMI;nipple discharge;Mass size;BI-RADS;Radiomic features;Pathomics features;Raman spectra;Genomics;Proteomics;Metabolomics;Transcriptomics;Mammogram breast density types;Biopsy Method;benign and malignant;Histological type;Molecular subtypes;Lymph Node Status;Neoadjuvant treatment programs;Surgical method;Whether or not pCR;Adjunctive therapy programs;survival status;postoperative recurrence;Accuracy;Sensitivity, SE;Specificity, SP;Positive predicative value, PPV, PV+;Negative predictive value, NPV,PV-;AUC;Hosmer-Lemeshow goodness-of-fit;follow-up time;hemoglobin concentration;Hematology Indicators;Tumor indicators;Immunocyte indicators;Cause of death;nation;marital status; | — |
Secondary
| Measure | Time frame |
|---|---|
| Location;Distance to nipple;Calcification;lipidomics;Immunomics;glycomics; | — |
Countries
China
Contacts
Public ContactPei Jing
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed